Aspire Biopharma (NASDAQ:ASBP) Raised to Sell at Wall Street Zen

Aspire Biopharma (NASDAQ:ASBP) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Aspire Biopharma Stock Up 6.5%

NASDAQ:ASBP opened at $2.21 on Friday. The stock has a market cap of $5.94 million, a P/E ratio of -4.42 and a beta of 0.81. The business’s 50-day moving average price is $4.07 and its two-hundred day moving average price is $11.74. Aspire Biopharma has a twelve month low of $1.65 and a twelve month high of $632.00.

Aspire Biopharma (NASDAQ:ASBP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($1.60) earnings per share for the quarter. The company had revenue of $0.00 million for the quarter.

Hedge Funds Weigh In On Aspire Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. CIBC Bancorp USA Inc. purchased a new position in Aspire Biopharma during the 3rd quarter valued at $28,000. Jane Street Group LLC raised its stake in Aspire Biopharma by 625.8% in the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after buying an additional 131,533 shares in the last quarter. Optivise Advisory Services LLC boosted its position in Aspire Biopharma by 120.9% during the 2nd quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock valued at $63,000 after acquiring an additional 128,660 shares in the last quarter. Crewe Advisors LLC grew its holdings in shares of Aspire Biopharma by 100.0% during the 2nd quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock worth $169,000 after acquiring an additional 313,427 shares during the period. Finally, Procyon Advisors LLC raised its position in shares of Aspire Biopharma by 558.3% in the 2nd quarter. Procyon Advisors LLC now owns 648,411 shares of the company’s stock worth $174,000 after acquiring an additional 549,911 shares in the last quarter. Institutional investors own 19.17% of the company’s stock.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.